Anzeige
❌
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: A2JD8X | ISIN: US92243A2006 | Ticker-Symbol: NB11
Tradegate
24.04.24
16:16 Uhr
0,690 Euro
+0,031
+4,62 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VAXART INC Chart 1 Jahr
5-Tage-Chart
VAXART INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,6520,66810:20
0,6530,67009:56

Aktuelle News zur VAXART Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.03.Vaxart, Inc.: Vaxart to Present at World Vaccine Congress Washington 2024 on April 38GlobeNewswire (USA)
20.03.Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)115GlobeNewswire (Europe)SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the"Company"or"Vaxart") today announced that the Compensation Committee of the Board of Directors approved...
► Artikel lesen
15.03.Earnings call: Vaxart reports progress in oral vaccine development10Investing.com
14.03.Vaxart Inc reports results for the quarter ended in December - Earnings Summary5Reuters
14.03.Vaxart, Inc. - S-8, Securities to be offered to employees in employee benefit plans2SEC Filings
14.03.Vaxart, Inc. - 10-K, Annual Report3SEC Filings
14.03.Recap: Vaxart Q4 Earnings4Benzinga.com
14.03.Vaxart, Inc.: Vaxart Provides Business Update and Reports Full Year 2023 Financial Results445GlobeNewswire (Europe)Significant progress made in preparing for a Phase 2b study evaluating Vaxart's oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator Topline data from Phase 1 norovirus study...
► Artikel lesen
14.03.Vaxart, Inc. - 8-K, Current Report2SEC Filings
13.03.Vaxart FY 2023 Earnings Preview6Seeking Alpha
13.03.Vaxart's Earnings: A Preview7Benzinga.com
07.03.Vaxart, Inc.: Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 145GlobeNewswire (USA)
06.03.Vaxart appoints Steven Lo as president, CEO, and director1Seeking Alpha
06.03.Vaxart appoints Steven Lo as new President and CEO2Investing.com
06.03.Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director104GlobeNewswire (Europe)Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart")...
► Artikel lesen
29.02.Vaxart, Inc. - 8-K, Current Report2SEC Filings
15.02.Vaxart, Inc. - 8-K, Current Report12SEC Filings
05.02.Vaxart, Inc.: Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge235GlobeNewswire (Europe)- Data served as foundation for current vaccine candidate for planned Phase 2 research - Vaxart vaccine candidates elicited strong antigen-specific serum IgG and IgA with neutralizing activity against...
► Artikel lesen
01.02.Biggest stock movers today: Vaxart, Rocket Lab, and more12Seeking Alpha
31.01.Vaxart spikes as B. Riley upgrades at long last after BARDA funding17Seeking Alpha
Seite:  1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1